Full Press Release Details
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at
Paris and Tarrytown, NY, October 24, 2024. Positive data from the phase 3 LIBERTY-CUPID Study C
evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU) who receive background therapy with antihistamines will be presented in a late-breaking oral presentation at
the American College of Allergy, Asthma and Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts. Results showed treatment with Dupixent significantly reduced itch and urticaria activity (itch and hive) scores from baseline,
and a higher proportion of patients achieved well-controlled disease status, compared to placebo.
Professor, Internal Medicine, Morsani College of Medicine at the University of South
Chronic spontaneous urticaria is an inflammatory skin condition that affects
patients with unpredictable episodes of intense itching and hives, often severely impacting their daily lives. These data confirm results seen in the previous Study A and reinforce the potential of Dupixent to significantly alleviate symptoms for
patients, helping them to better control this challenging disease.
Study C enrolled 151 children and adults who were randomized to receive Dupixent
(n=74) or placebo (n=77) added to standard-of-care histamine-1 (H1) antihistamines. At 24 weeks, Dupixent demonstrated
significant improvements compared to placebo on:
The safety results in Study C were generally consistent with the known safety profile of Dupixent in its approved dermatological indications. Overall rates of treatment
emergent adverse events (AEs) were 53% for both Dupixent and placebo. AEs more commonly observed with Dupixent ( 5%) compared to placebo included injection site reactions (12% vs. 4%),
accidental overdose (7% vs. 3%) and COVID-19 infection (8% vs. 5%).
Dupixent has been approved for CSU in Japan, the United Arab Emirates (UAE) and is also under regulatory review in the
European Union based on earlier trial readouts. Outside of Japan and the UAE, the safety and efficacy of Dupixent for CSU has not been fully evaluated by any regulatory authority.
CSU is a chronic inflammatory skin disease driven in part by type-2 inflammation, which causes sudden and debilitating hives and persistent itch. CSU is typically treated with H1 antihistamines, medicines that target H1 receptors on cells to control symptoms of urticaria.
However, the disease remains uncontrolled despite antihistamine treatment in many patients, some of whom are left with limited alternative treatment options. These individuals continue to experience symptoms that can be debilitating and
significantly impact their quality of life. More than 300,000 people in the US suffer from CSU that is inadequately controlled by antihistamines.
Dupixent phase 3 CSU program (LIBERTY-CUPID)
The LIBERTY-CUPID Phase 3 study program evaluating Dupixent for CSU consists of Study A, Study B, and
Study C was a randomized,
double-blind, placebo-controlled clinical study that evaluated the efficacy and safety of Dupixent as an add-on to
standard-of-care antihistamines compared to antihistamines alone in 151 patients aged six years and older with CSU who remained symptomatic despite antihistamine use and
were not previously treated with omalizumab (i.e., biologic-na ve). The primary endpoint assessed the change from baseline in itch at 24 weeks (measured by the weekly itch severity score [ISS7], 0-21 scale). Secondary endpoints at 24 weeks, measured by the weekly urticaria activity score (UAS7) included the change from baseline in itch and hives (UAS7, 0-42 scale),
proportion of patients achieving well-controlled disease status (UAS7 6), and complete response (UAS7=0).
Dupixent (dupilumab) is a fully human monoclonal antibody
that inhibits the signaling of the IL4 and IL13 pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type-2 inflammation in phase
3 studies, establishing that IL4 and IL13 are two of the key and central drivers of type-2 inflammation that play a major role in multiple related and often co-morbid
Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis,
asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and chronic obstructive pulmonary disease in different age populations. More than 1,000,000 patients are being treated with
Dupilumab development program
jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type-2 inflammation.
In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of
diseases driven in part by type-2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin and bullous pemphigoid. These potential uses of dupilumab are
currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with
serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown
in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases,
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as
VelociSuite , which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center and pioneering genetic
medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please
visit www.Regeneron.com or follow Regeneron on
LinkedIn, Instagram,
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people s lives. Our team, across
the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while
putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Sanofi Media Relations
Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | + 1 215 432 0234 | evan.berland@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 |
Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com
Sanofi Investor Relations
Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Aliz Kaisserian | + 33 6 47 04 12 11 |
Del pine | + 33 6 73 69 36 93 |arnaud.delepine@sanofi.com
Felix Lauscher | + 1 908 612 7239 |
Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni | + 1 617 710 3587 |
Ch telet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Regeneron Media Relations
Yellen | +1 914-330-9618| ilana.yellen@regeneron.com
Regeneron Investor Relations
Mark Hudson | + 914-847-3482 | mark.hudson@regeneron.com
Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking
statements are generally identified by the words expects , anticipates , believes , intends , estimates , plans and similar expressions. Although Sanofi s management believes
that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include
among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties
inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks
associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in
the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Sanofi s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
All trademarks mentioned in this press release are the property of the Sanofi group with the exception of VelociSuite and Regeneron Genetics Center.
Regeneron Forward-Looking Statements and Use of Digital Media
release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ( Regeneron or the Company ), and actual events or results
may differ materially from these forward-looking statements. Words such as anticipate, expect, intend, plan, believe, seek, estimate, variations of such words, and
similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature,
timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, Regeneron s Products ) and product candidates being
developed by Regeneron and/or its collaborators or licensees (collectively, Regeneron s Product Candidates ) and research and clinical programs now underway or planned, including without limitation Dupixent (dupilumab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron s Product Candidates and new indications for Regeneron s Products, such
as Dupixent for the treatment of chronic spontaneous urticaria ( CSU ) as discussed in this press release as well as the treatment of chronic pruritus of unknown origin, bullous pemphigoid, and other potential indications; uncertainty of
the utilization, market acceptance, and commercial success of Regeneron s Products and Regeneron s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the
studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron s Products (such as Dupixent for the treatment of CSU in countries other than Japan and the United Arab Emirates)
and Regeneron s Product Candidates; the ability of Regeneron s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps
related to Regeneron s Products and Regeneron s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron s Products
(such as Dupixent) and Regeneron s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron s Products and Regeneron s Product Candidates in clinical trials;
determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron s ability to continue to develop or commercialize Regeneron s Products and Regeneron s Product Candidates; ongoing
regulatory obligations and oversight impacting Regeneron s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron s Products from
third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations
by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron s Products and Regeneron s Product Candidates; the extent to